Loading …
Never Run Out Of Buyers To Sell To.

Pioneering a New Era of Neuroregeneration As the first company to demonstrate in vivo nerve regeneration via 5-HT2A modulation, we are advancing precision agonists to restore neural circuitry and immune balance.
Annual Revenue$1M to $5M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.